When destiny doesn’t pan out: Implications for the treatment of sarcomas after the agnostic approval of trastuzumab deruxtecan
In April 2024, the Food and Drug Administration provided accelerated approval for trastuzumab deruxtecan for adult patients with advanced solid tumors which have positive immunochemical staining for HER2 expression, including sarcomas. There should be ample consideration prior to utilization of trastuzumab deruxtecan for patients with sarcomas, as HER2 targeted therapy has been ineffective in certain subtypes.
Authors
- Timothée Olivier (ORCID: https://orcid.org/0000-0002-6936-5783)
- Brian Schulte (ORCID: https://orcid.org/0000-0002-3364-9872)
- Andrew Horvai (ORCID: https://orcid.org/0000-0002-8066-7889)
- Caleb Hwang (ORCID: https://orcid.org/0009-0005-1986-8357)
Institutions
- University of California, San Francisco (US)
- University Hospital of Geneva (CH)
- UCSF Helen Diller Family Comprehensive Cancer Center (US)
Publication Details
- Journal
- Cancer
- Published
- 2024-08-25
- DOI
- https://doi.org/10.1002/cncr.35539
- Citations
- 2
- Primary Topic
- Sarcoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.84